Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections

Launched by METHODIST HEALTH SYSTEM · Oct 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how long patients with bloodstream infections caused by the bacteria Streptococcus pneumoniae should receive antibiotic treatment. The researchers want to compare two different treatment lengths: a shorter duration and a longer duration, to see which is more effective and safe. Streptococcus pneumoniae can cause serious infections and is a common cause of bloodstream infections that can lead to severe illness and even death.

To participate in the trial, you must be at least 18 years old and have tested positive for Streptococcus pneumoniae in your blood. You should also be receiving active intravenous (IV) antibiotic treatment within 48 hours of your first positive blood test and be stable by the tenth day of treatment. Participants will be monitored throughout the study to determine the effectiveness of the different treatment durations. This trial is currently recruiting participants of all genders, and it aims to help improve treatment guidelines for this serious infection.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • ≥18 years of age
• • S. pneumoniae isolated from ≥1 blood cultures
• • Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8)
• • Clinical stability by day 10 of therapy
• Exclusion Criteria:
• • • Treatment duration \<5 days or \>16 days
• • Death before completion of therapy (\<10 days vs. ≥ 10 days )
• • Polymicrobial BSI
• • Invasive infection caused by S. pneumoniae (endocarditis, meningitis, and lung abscess)